JOHANNESBURG, South Africa – To support the development of vaccines for African countries, U.S. International Development Finance Corporation (DFC), IFC, the French Development institution Proparco, and DEG - the German development finance institution, today announced a joint financing package for Aspen Pharmacare Holdings Limited, a leading pharmaceutical company in South Africa that is playing a major role producing COVID-19 treatment therapies and vaccines on the African continent.
The €600 million long-term financing package, which is subject to the fulfillment of certain conditions precedent, is mobilized by IFC, the private sector arm of the World Bank Group. It includes €200 million from IFC’s own account, €156 million from Proparco, a subsidiary of Agence Française de Développement (AFD Group), €144 million arranged by DEG, and €100 million from DFC. It’s the largest healthcare investment and mobilization IFC has led globally to date.
The announcement about the financing package for Aspen also comes as governments across Africa have called on the international community to bolster the continent’s vaccine supply chain to respond to COVID-19 and promote longer-term health sector resilience.
The financing will help Aspen, Africa’s largest pharmaceutical company, to refinance existing debt and strengthen the company’s balance sheet, supporting Aspen’s operations including production of vaccines, and other therapies in African and emerging markets. The four development finance institutions also have the objective of helping to facilitate an increase in vaccine manufacturing know-how and knowledge sharing within Africa by partnering with Aspen.
Aspen is expanding its role in fighting the COVID-19 pandemic in Africa. Aspen has partnered with Johnson & Johnson to compound, finish, fill and package the Janssen (a Johnson & Johnson company) COVID-19 vaccine at its sterile facility in South Africa. Aspen has recently built a fully certified sterile injectables facility at its existing site at Gqeberha (formally known as Port Elizabeth), South Africa. With this new facility, Aspen was able to offer Johnson & Johnson filling, finishing and packaging capacity for its COVID-19 vaccine, with the first batches having already been manufactured.
“We are grateful for the opportunity to access this funding package arranged by IFC. Aspen’s teams are working tirelessly to optimize production of the Johnson & Johnson COVID-19 vaccine for Africa at our manufacturing site in Gqeberha, South Africa. We are actively seeking opportunities to further extend and capacitate COVID-19 vaccine manufacturing at this world class production facility. Aspen is seeking to play a meaningful role in contributing to the objective of delivering the majority of Africa’s needs from production sites located in Africa,” said Stephen Saad, Aspen’s Group Chief Executive.
“COVID-19 has again highlighted Africa’s reliance on global vaccine supply chains, leaving the continent vulnerable to disruptions and delays,” said Makhtar Diop, IFC’s Managing Director. “By partnering with Aspen, a leading vaccine manufacturer in Africa, and collaborating with partners in the development finance community, the World Bank Group can contribute to the continent’s continued vaccine manufacturing development and support knowledge sharing and technology exchanges. Together, we hope this will save lives now and help ensure that Africa is prepared ahead of any future health crises.”
The African Union and Africa CDC announced in April 2021 an ambition for Africa to manufacture 60 percent of its vaccine needs on the continent by 2040. Currently, Africa manufactures only about one percent of the vaccines it uses.
“French President Emmanuel Macron committed to investing in enabling the production of vaccines in Africa, for local production will be key to win the battle against COVID-19. Today, I am proud that the AFD Group, through its private-sector arm Proparco, partners with other development finance institutions and Aspen, one of the major pharmaceutical companies in Africa and a ‘front-liner’ manufacturer of COVID-19 drugs and vaccines, to help close a gap in the availability of the shots between African and Western nations. This project shows that global public goods require financing in common, to which public development banks are ready to contribute,” said Remy Rioux, CEO of AFD Group and President of Proparco.
“DEG’s mission is to be a reliable partner to private sector enterprises as drivers of development and creators of qualified jobs. We are pleased to contribute to this vaccine production in Africa together with our development finance partner institutions. We are convinced that it is essential to join forces to fight the pandemic effectively, and the private sector plays a key role in this,” said Monika Beck, Member of DEG’s Management Board.
“DFC is proud to be working with our partners at IFC, Proparco, and DEG to support critical vaccine production efforts on the African continent, in alignment with President Biden’s strategy to bring an end to the pandemic. The DFC’s support for Aspen expands critical manufacturing abroad, in Africa, for Africa,” said DFC’s Chief Operating Officer David Marchick. “This project is the first of many that will help build local capacity and create self-reliance for regions around the world, and will help immediately address the current pandemic while also boosting future pandemic preparedness efforts.”
The World Bank Group has been scaling up support to countries to produce, acquire and deliver vaccines to more people, particularly in Africa. The World Bank Group is providing billions of dollars in vaccine financing to help countries purchase and distribute vaccines in order to address readiness issues. IFC's investment in Aspen falls under its Global Health Platform launched in July 2020 to help developing countries fight the coronavirus pandemic and increase their healthcare systems' resilience. Including this new project, IFC has committed $1.82 billion in COVID-19 related projects since March 2020, of which $1.15 million falls under the Global Health Platform (GHP) that was created specifically to support vaccines and related initiatives.
Proparco’s investment is part of the initiative launched in April 2020 by the French President and implemented by AFD Group, “COVID-19 – Health in Common” – a €1.2 billion initiative in response to the worldwide public health crisis caused by the COVID-19 pandemic. This French program is being further reinforced in 2021 and is part of a European effort to mount a targeted, partnership-based response to this unprecedented crisis facing developing countries. It complements the work of multilateral and European donors and prioritizes the African continent.
DFC’s investment is part of the agency’s Health and Prosperity initiative which is focused on supporting the global response to the COVID-19 pandemic and strengthening health resilience in developing countries. Through the initiative, DFC is working to invest $2 billion in projects that bolster health systems, support infrastructure development, and expand access to clean water, sanitation, and nutrition.
U.S. International Development Finance Corporation (DFC) is America's development bank. DFC partners with the private sector to finance solutions to the most critical challenges facing the developing world today. We invest across sectors including energy, healthcare, critical infrastructure, and technology. DFC also provides financing for small businesses and women entrepreneurs in order to create jobs in emerging markets. DFC investments adhere to high standards and respect the environment, human rights, and worker rights. The United States is working with the private sector and all possible partners to expand global vaccine manufacturing and distribution targeting investments in multiple regions of the world both to address short-term crisis response requirements as well as intermediate-term efforts to ensure better global preparedness for future health challenges. To learn more, visit www.dfc.gov.
Headquartered in Durban, South Africa, Aspen is a leading global specialty and branded multinational pharmaceutical company in both emerging and developed markets. With an acknowledged presence of more than two decades in the pharmaceutical sector, Aspen improves the health of patients in more than 150 countries through its high quality, affordable and effective healthcare solutions. The Group’s key business segments are Manufacturing and Commercial Pharmaceuticals (comprising Regional Brands and Sterile Focus Brands) that include Anaesthetics and Thrombosis products. Aspen employs approximately 9 800 people and has 70 established business operations in over 50 countries. The Group operates 23 manufacturing facilities across 15 sites and holds international manufacturing approvals from some of the most stringent global regulatory agencies. Its manufacturing capabilities are scalable to demand and cover a wide variety of product-types including steriles, oral solid dose, liquids, semi-solids, biologicals and active pharmaceutical ingredients. For more information visit www.aspenpharma.com.
IFC—a member of the World Bank Group—is the largest global development institution focused on the private sector in emerging markets. We work in more than 100 countries, using our capital, expertise, and influence to create markets and opportunities in developing countries. In fiscal year 2020, we invested $22 billion in private companies and financial institutions in developing countries, leveraging the power of the private sector to end extreme poverty and boost shared prosperity. For more information, visit www.ifc.org.
Proparco is the private sector financing arm of Agence Française de Développement Group (AFD Group). It has been promoting sustainable economic, social and environmental development for over 40 years. Proparco provides funding and support to both businesses and financial institutions in Africa, Asia, Latin America and the Middle East. Its action focuses on the key development sectors: infrastructure, mainly for renewable energies, agribusiness, financial institutions, health and education. Its operations aim to strengthen the contribution of private players to the achievement of the Sustainable Development Goals (SDGs) adopted by the international community in 2015. To this end, Proparco finances companies whose activity contributes to creating jobs and decent incomes, providing essential goods and services and combating climate change. For a World in Common. For further information: www.proparco.fr/en and @Proparco.
For almost 60 years DEG has been a reliable partner to private-sector enterprises operating in developing and emerging-market countries. We provide our customers with tailor-made solutions, including financing, promotional programmes and advice tailored to individual needs. They can thus develop successfully and sustainably, while generating local added value and creating qualified jobs. With our portfolio of around EUR 8.5 billion in approximately 80 countries we're one of the world's largest private-sector development financiers. Learn more: www.deginvest.de.